napp pharmaceuticals limited
napp pharmaceuticals limited Company Information
Company Number
03690299
Website
www.napp.co.ukRegistered Address
unit 196 cambridge science park, milton road, cambridge, CB4 0AB
Industry
Wholesale of pharmaceutical goods
Telephone
01223424444
Next Accounts Due
September 2024
Group Structure
View All
napp pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of NAPP PHARMACEUTICALS LIMITED at £86m based on a Turnover of £70.4m and 1.22x industry multiple (adjusted for size and gross margin).
napp pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of NAPP PHARMACEUTICALS LIMITED at £16.1m based on an EBITDA of £1.7m and a 9.59x industry multiple (adjusted for size and gross margin).
napp pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of NAPP PHARMACEUTICALS LIMITED at £20.2m based on Net Assets of £9.6m and 2.11x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Napp Pharmaceuticals Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Napp Pharmaceuticals Limited Overview
Napp Pharmaceuticals Limited is a live company located in cambridge, CB4 0AB with a Companies House number of 03690299. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in December 1998, it's largest shareholder is napp pharmaceutical holdings ltd with a 99.6% stake. Napp Pharmaceuticals Limited is a mature, large sized company, Pomanda has estimated its turnover at £70.4m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Napp Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Napp Pharmaceuticals Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 7 areas for improvement. Company Health Check FAQs
4 Strong
0 Regular
7 Weak
Size
annual sales of £70.4m, make it larger than the average company (£25.8m)
£70.4m - Napp Pharmaceuticals Limited
£25.8m - Industry AVG
Growth
3 year (CAGR) sales growth of -23%, show it is growing at a slower rate (4.6%)
-23% - Napp Pharmaceuticals Limited
4.6% - Industry AVG
Production
with a gross margin of 20.7%, this company has a higher cost of product (26.3%)
20.7% - Napp Pharmaceuticals Limited
26.3% - Industry AVG
Profitability
an operating margin of 2.4% make it less profitable than the average company (4%)
2.4% - Napp Pharmaceuticals Limited
4% - Industry AVG
Employees
with 49 employees, this is above the industry average (38)
49 - Napp Pharmaceuticals Limited
38 - Industry AVG
Pay Structure
on an average salary of £111.7k, the company has a higher pay structure (£72.3k)
£111.7k - Napp Pharmaceuticals Limited
£72.3k - Industry AVG
Efficiency
resulting in sales per employee of £1.4m, this is more efficient (£607k)
£1.4m - Napp Pharmaceuticals Limited
£607k - Industry AVG
Debtor Days
it gets paid by customers after 35 days, this is earlier than average (59 days)
35 days - Napp Pharmaceuticals Limited
59 days - Industry AVG
Creditor Days
its suppliers are paid after 10 days, this is quicker than average (28 days)
10 days - Napp Pharmaceuticals Limited
28 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Napp Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (12 weeks)
0 weeks - Napp Pharmaceuticals Limited
12 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 64.7%, this is a higher level of debt than the average (56.5%)
64.7% - Napp Pharmaceuticals Limited
56.5% - Industry AVG
napp pharmaceuticals limited Credit Report and Business Information
Napp Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for napp pharmaceuticals limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
napp pharmaceuticals limited Ownership
NAPP PHARMACEUTICALS LIMITED group structure
Napp Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
1 parent
NAPP PHARMACEUTICALS LIMITED
03690299
napp pharmaceuticals limited directors
Napp Pharmaceuticals Limited currently has 3 directors. The longest serving directors include Mr Bryan Lea (Jan 2003) and Mr Hywel Day (Jan 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Bryan Lea | 62 years | Jan 2003 | - | Director | |
| Mr Hywel Day | England | 50 years | Jan 2017 | - | Director |
| Mr Stephen Jamieson | England | 66 years | Feb 2019 | - | Director |
NAPP PHARMACEUTICALS LIMITED financials
Napp Pharmaceuticals Limited's latest turnover from December 2022 is £70.4 million and the company has net assets of £9.6 million. According to their latest financial statements, Napp Pharmaceuticals Limited has 49 employees and maintains cash reserves of £15 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 70,404,000 | 99,815,000 | 123,872,000 | 152,741,000 | 144,974,000 | 126,867,000 | 127,816,000 | 134,202,000 | 143,972,000 | 135,114,000 | 133,376,000 | 118,702,000 | 108,009,000 | 95,893,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 55,855,000 | 80,018,000 | 86,746,000 | 107,720,000 | 102,311,000 | 87,402,000 | 91,545,000 | 94,733,000 | 105,311,000 | 99,749,000 | 92,666,000 | 78,857,000 | 71,922,000 | 64,265,000 |
| Gross Profit | 14,549,000 | 19,797,000 | 37,126,000 | 45,021,000 | 42,663,000 | 39,465,000 | 36,271,000 | 39,469,000 | 38,661,000 | 35,365,000 | 40,710,000 | 39,845,000 | 36,087,000 | 31,628,000 |
| Admin Expenses | 12,868,000 | 16,862,000 | 32,763,000 | 40,719,000 | 37,998,000 | 35,287,000 | 32,491,000 | 33,838,000 | 30,996,000 | 31,983,000 | 32,076,000 | 29,985,000 | 29,559,000 | 25,873,000 |
| Operating Profit | 1,681,000 | 2,935,000 | 4,363,000 | 4,302,000 | 4,665,000 | 4,178,000 | 3,780,000 | 5,631,000 | 7,665,000 | 3,382,000 | 8,634,000 | 9,860,000 | 6,528,000 | 5,755,000 |
| Interest Payable | 0 | 0 | 0 | 0 | 326,000 | 177,000 | 0 | 0 | 0 | 0 | 0 | 306,000 | 322,000 | 197,000 |
| Interest Receivable | 8,000 | 82,000 | 126,000 | 255,000 | 0 | 0 | 179,000 | 111,000 | 108,000 | 183,000 | 205,000 | 136,000 | 63,000 | 111,000 |
| Pre-Tax Profit | 1,689,000 | 3,017,000 | 4,489,000 | 4,568,000 | 4,350,000 | 3,806,000 | 3,834,000 | 5,574,000 | 7,699,000 | 3,565,000 | 8,839,000 | 9,690,000 | 6,269,000 | 5,669,000 |
| Tax | -340,000 | -578,000 | -1,037,000 | -1,027,000 | -1,000,000 | -981,000 | -945,000 | -1,501,000 | -1,673,000 | -1,107,000 | -2,326,000 | -2,826,000 | -2,046,000 | -1,952,000 |
| Profit After Tax | 1,349,000 | 2,439,000 | 3,452,000 | 3,541,000 | 3,350,000 | 2,825,000 | 2,889,000 | 4,073,000 | 6,026,000 | 2,458,000 | 6,513,000 | 6,864,000 | 4,223,000 | 3,717,000 |
| Dividends Paid | 784,000 | 0 | 0 | 0 | 7,000,000 | 15,500,000 | 0 | 0 | 20,000,000 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 565,000 | 2,439,000 | 3,452,000 | 3,541,000 | -3,650,000 | -12,675,000 | 2,889,000 | 4,073,000 | -13,974,000 | 2,458,000 | 6,513,000 | 6,864,000 | 4,223,000 | 3,717,000 |
| Employee Costs | 5,474,000 | 9,285,000 | 17,679,000 | 18,515,000 | 16,095,000 | 14,615,000 | 14,213,000 | 18,928,000 | 16,014,000 | 16,291,000 | 15,004,000 | 15,608,000 | 18,412,000 | 17,941,000 |
| Number Of Employees | 49 | 68 | 170 | 196 | 190 | 176 | 173 | 227 | 216 | 222 | 212 | 236 | 274 | 302 |
| EBITDA* | 1,683,000 | 2,939,000 | 4,368,000 | 4,309,000 | 4,676,000 | 4,195,000 | 3,824,000 | 5,687,000 | 7,701,000 | 3,435,000 | 8,654,000 | 9,977,000 | 6,739,000 | 6,079,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,000 | 3,000 | 7,000 | 12,000 | 12,000 | 16,000 | 624,000 | 945,000 | 922,000 | 123,000 | 164,000 | 179,000 | 506,000 | 883,000 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 20,000 | 17,000 | 20,000 | 21,000 | 22,000 | 25,000 | 1,266,000 | 614,000 | 905,000 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 21,000 | 20,000 | 27,000 | 33,000 | 34,000 | 41,000 | 1,890,000 | 1,559,000 | 1,827,000 | 123,000 | 164,000 | 179,000 | 506,000 | 883,000 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 6,785,000 | 10,394,000 | 13,253,000 | 31,997,000 | 40,225,000 | 30,441,000 | 35,949,000 | 39,181,000 | 36,152,000 | 30,796,000 | 28,716,000 | 25,520,000 | 23,769,000 | 20,724,000 |
| Group Debtors | 20,064,000 | 7,777,000 | 6,053,000 | 0 | 0 | 0 | 1,475,000 | 0 | 0 | 2,193,000 | 7,352,000 | 2,109,000 | 0 | 0 |
| Misc Debtors | 251,000 | 219,000 | 668,000 | 1,061,000 | 1,208,000 | 11,091,000 | 1,408,000 | 429,000 | 722,000 | 733,000 | 645,000 | 1,823,000 | 1,449,000 | 802,000 |
| Cash | 15,000 | 17,000 | 20,000 | 24,000 | 29,000 | 39,000 | 0 | 19,000 | 19,000 | 23,000 | 892,000 | 932,000 | 15,732,000 | 9,651,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 27,115,000 | 18,407,000 | 19,994,000 | 33,082,000 | 41,462,000 | 41,571,000 | 38,832,000 | 39,629,000 | 36,893,000 | 33,745,000 | 37,605,000 | 30,384,000 | 40,950,000 | 31,177,000 |
| total assets | 27,136,000 | 18,427,000 | 20,021,000 | 33,115,000 | 41,496,000 | 41,612,000 | 40,722,000 | 41,188,000 | 38,720,000 | 33,868,000 | 37,769,000 | 30,563,000 | 41,456,000 | 32,060,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 1,632,000 | 2,730,000 | 1,733,000 | 1,784,000 | 1,051,000 | 1,629,000 | 1,303,000 | 824,000 | 848,000 | 1,148,000 | 2,060,000 | 1,785,000 | 2,270,000 | 1,058,000 |
| Group/Directors Accounts | 0 | 0 | 0 | 12,516,000 | 27,544,000 | 7,209,000 | 0 | 5,011,000 | 15,214,000 | 0 | 0 | 0 | 18,138,000 | 13,106,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39,000 | 244,000 | 364,000 |
| other current liabilities | 15,826,000 | 5,920,000 | 10,086,000 | 13,677,000 | 10,622,000 | 26,283,000 | 18,003,000 | 17,288,000 | 8,180,000 | 4,734,000 | 10,176,000 | 9,779,000 | 8,642,000 | 9,287,000 |
| total current liabilities | 17,458,000 | 8,650,000 | 11,819,000 | 27,977,000 | 39,217,000 | 35,121,000 | 19,306,000 | 23,123,000 | 24,242,000 | 5,882,000 | 12,236,000 | 11,603,000 | 29,294,000 | 23,815,000 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66,000 | 327,000 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 89,000 | 81,000 | 278,000 | 0 | 0 | 0 | 0 | 0 | 0 | 55,000 | 60,000 | 0 | 0 | 45,000 |
| total long term liabilities | 89,000 | 81,000 | 278,000 | 0 | 0 | 0 | 7,785,000 | 3,491,000 | 4,741,000 | 55,000 | 60,000 | 0 | 66,000 | 372,000 |
| total liabilities | 17,547,000 | 8,731,000 | 12,097,000 | 27,977,000 | 39,217,000 | 35,121,000 | 27,091,000 | 26,614,000 | 28,983,000 | 5,937,000 | 12,296,000 | 11,603,000 | 29,360,000 | 24,187,000 |
| net assets | 9,589,000 | 9,696,000 | 7,924,000 | 5,138,000 | 2,279,000 | 6,491,000 | 13,631,000 | 14,574,000 | 9,737,000 | 27,931,000 | 25,473,000 | 18,960,000 | 12,096,000 | 7,873,000 |
| total shareholders funds | 9,589,000 | 9,696,000 | 7,924,000 | 5,138,000 | 2,279,000 | 6,491,000 | 13,631,000 | 14,574,000 | 9,737,000 | 27,931,000 | 25,473,000 | 18,960,000 | 12,096,000 | 7,873,000 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 1,681,000 | 2,935,000 | 4,363,000 | 4,302,000 | 4,665,000 | 4,178,000 | 3,780,000 | 5,631,000 | 7,665,000 | 3,382,000 | 8,634,000 | 9,860,000 | 6,528,000 | 5,755,000 |
| Depreciation | 2,000 | 4,000 | 5,000 | 7,000 | 11,000 | 17,000 | 44,000 | 56,000 | 36,000 | 53,000 | 20,000 | 117,000 | 211,000 | 324,000 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -340,000 | -578,000 | -1,037,000 | -1,027,000 | -1,000,000 | -981,000 | -945,000 | -1,501,000 | -1,673,000 | -1,107,000 | -2,326,000 | -2,826,000 | -2,046,000 | -1,952,000 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 8,713,000 | -1,587,000 | -13,085,000 | -8,376,000 | -102,000 | 1,459,000 | -126,000 | 2,445,000 | 4,057,000 | -2,991,000 | 7,261,000 | 4,234,000 | 3,692,000 | 21,526,000 |
| Creditors | -1,098,000 | 997,000 | -51,000 | 733,000 | -578,000 | 326,000 | 479,000 | -24,000 | -300,000 | -912,000 | 275,000 | -485,000 | 1,212,000 | 1,058,000 |
| Accruals and Deferred Income | 9,906,000 | -4,166,000 | -3,591,000 | 3,055,000 | -15,661,000 | 8,280,000 | 715,000 | 9,108,000 | 3,446,000 | -5,442,000 | 397,000 | 1,137,000 | -645,000 | 9,287,000 |
| Deferred Taxes & Provisions | 8,000 | -197,000 | 278,000 | 0 | 0 | 0 | 0 | 0 | -55,000 | -5,000 | 60,000 | 0 | -45,000 | 45,000 |
| Cash flow from operations | 1,446,000 | 582,000 | 13,052,000 | 15,446,000 | -12,461,000 | 10,361,000 | 4,199,000 | 10,825,000 | 5,062,000 | -1,040,000 | -201,000 | 3,569,000 | 1,523,000 | -7,009,000 |
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | -12,516,000 | -15,028,000 | 20,335,000 | 7,209,000 | -5,011,000 | -10,203,000 | 15,214,000 | 0 | 0 | -18,138,000 | 5,032,000 | 13,106,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -39,000 | -271,000 | -381,000 | 691,000 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 8,000 | 82,000 | 126,000 | 255,000 | -326,000 | -177,000 | 179,000 | 111,000 | 108,000 | 183,000 | 205,000 | -170,000 | -259,000 | -86,000 |
| cash flow from financing | -664,000 | -585,000 | -13,056,000 | -15,455,000 | 19,447,000 | 12,567,000 | -8,664,000 | -9,328,000 | 11,102,000 | 183,000 | 166,000 | -18,579,000 | 4,392,000 | 17,867,000 |
| cash and cash equivalents | ||||||||||||||
| cash | -2,000 | -3,000 | -4,000 | -5,000 | -10,000 | 39,000 | -19,000 | 0 | -4,000 | -869,000 | -40,000 | -14,800,000 | 6,081,000 | 9,651,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -2,000 | -3,000 | -4,000 | -5,000 | -10,000 | 39,000 | -19,000 | 0 | -4,000 | -869,000 | -40,000 | -14,800,000 | 6,081,000 | 9,651,000 |
P&L
December 2022turnover
70.4m
-29%
operating profit
1.7m
-43%
gross margin
20.7%
+4.19%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
9.6m
-0.01%
total assets
27.1m
+0.47%
cash
15k
-0.12%
net assets
Total assets minus all liabilities
Similar Companies
napp pharmaceuticals limited company details
company number
03690299
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
December 1998
age
26
accounts
Full Accounts
ultimate parent company
previous names
N/A
incorporated
UK
address
unit 196 cambridge science park, milton road, cambridge, CB4 0AB
last accounts submitted
December 2022
napp pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to napp pharmaceuticals limited. Currently there are 1 open charges and 0 have been satisfied in the past.
napp pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
